Quick Answer
NEPHROS INC reported Cash And Cash Equivalents At Carrying Value of $5.40 million for the year ending 2025.
- NEPHROS INC showed an increase of +43.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NEPHROS INC's annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $8.96 million | Q2 2020: $7.05 million | Q3 2020: $5.16 million | Q1 2021: $8.16 million | Q2 2021: $8.28 million | Q3 2021: $7.35 million | Q1 2022: $5.42 million | Q2 2022: $4.18 million | Q3 2022: $3.94 million | Q1 2023: $3.84 million | Q2 2023: $4.06 million | Q3 2023: $4.62 million | Q1 2024: $3.63 million | Q2 2024: $3.08 million | Q3 2024: $2.46 million | Q1 2025: $4.08 million | Q2 2025: $5.07 million | Q3 2025: $5.17 million.
- Over the full 7 years of available data (2019 to 2025), NEPHROS INC's Cash And Cash Equivalents At Carrying Value has grown by 29.6%.
- Historical annual values: Fiscal year 2025: $5.40 million | Fiscal year 2024: $3.76 million | Fiscal year 2023: $4.31 million | Fiscal year 2022: $3.63 million | Fiscal year 2021: $6.97 million | Fiscal year 2020: $8.25 million | Fiscal year 2019: $4.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: